Cabotegravir is a potent HIV integrase inhibitor as an oral lead-in tablet and long-acting injectable for the treatment and prevention of HIV infection. Cabotegravir is an inhibitor of OAT1 (IC50 0.81 μM) and OAT3 (IC50 0.41 μM).
IC50 value: 0.81 μM (OAT1), 0.41 μM (OAT3) [1]
Target: OAT1, OAT3
Cabotegravir is a potent HIV integrase inhibitor in clinical development as an oral lead-in tablet and long-acting injectable for the treatment and prevention of HIV infection.[2] Cabotegravir is an HIV-1 integrase inhibitor under development as a tablet for both oral lead-in therapy and long-acting (LA) injectable for intramuscular dosing.[3]
分子式
C19H17F2N3O5
分子量
405.35
CAS号
1051375-10-0
中文名称
卡博特韦
运输条件
Room temperature in continental US; may vary elsewhere.